Keyword: U.S. Supreme Court
Prosecutors are looking for ways to hold Purdue's founding family accountable for their role in the opioid epidemic. Arizona’s AG may have found one.
Eli Lilly has a message for SCOTUS: We won’t take a $20 million patent loss for Cialis sitting down. Now, some friends are joining the fray.
Swamped with generics, Eli Lilly’s Cialis is on the ropes. But to protect its Cialis patent in prostate disease, Lilly is taking the fight to SCOTUS.
GSK prevailed in its Paxil preemption case as the Supreme Court denied taking up a lower court's decision to throw out a $3 million jury verdict.
Merck & Co.'s Fosamax fight has lasted for years—and now, thanks to a U.S. Supreme Court ruling Monday, Merck gets yet another chance to press its case.
Allergan took its tribal licensing deal all the way to the Supreme Court, which declined to hear the case.
Can tribal immunity shield a drug—in this case, Restasis—from a patent challenge? Allergan and the Mohawk tribe want the Supreme Court to weigh in.
Amgen failed to keep Repatha rival Praluent off the market with a patent challenge, but it's hoping more price cuts will help it grab market share.
In oral arguments Monday, liberal Justice Breyer and several conservative Justices appeared to support Merck's defense.
Monday was a good-news-bad-news day for Gilead as the Supreme Court handed down two decisions about which appeals they'll consider.